Surrogate endpoints: A basis for a rational approach

  title={Surrogate endpoints: A basis for a rational approach},
  author={Jean-Pierre Boissel and J. -P. Collet and P. Moleur and Margaret Haugh},
  journal={European Journal of Clinical Pharmacology},
In clinical trials, the clinical endpoint is often replaced by an intermediate endpoint, known in some instances as a “surrogate” endpoint. The reasons for the substitution are often both practical and financial. At present, no theoretical basis or practical guidelines exist to help in the choice of surrogate endpoints. An approach is proposed here, based on three provisos which can be verified using one of a series of equations, if sufficient data on the pathophysiology and epidemiology of the… CONTINUE READING

From This Paper

Figures and tables from this paper.


Publications citing this paper.
Showing 1-10 of 46 extracted citations


Publications referenced by this paper.
Showing 1-10 of 21 references

Blood pressure, stroke, and coronary heart disease. Part 2. shortterm reduction s in blood pressure: overview of randomized drug trials in epidemiological

  • R Collins, R Peto, +6 authors CH Hennekens
  • 1990
1 Excerpt

High blood pressure and clinical events linked with atherosclerosis

  • JP Boissel, F Gueyffier
  • Transmedico Europe Ltd, UK,
  • 1990
1 Excerpt

Clinical predictors of arrhythmia worsening by antiarrhythmic drugs

  • RL Prentice
  • Am J Cardiol
  • 1989

Crit 6 res interm 6diaires et crithres de substitution dans le d 6 veloppement des antiarythmiques

  • LK Hine, NM Laird, TC HewittRChalmers
  • Arch Mal Coeur
  • 1989

Meta analysis of empirical antiarrhythmic therapy after myocardial infarction

  • LK Hine, NM Laird, TC Hewitt R Chalmers
  • J Am Med Assoc
  • 1989
1 Excerpt

Similar Papers

Loading similar papers…